12 Nov. 2024 J. Molner AS launches Lidocaine HCL Topical Solution USP, 4% in the United States
22 Oct. 2024 J. Molner Announces New Chief Financial Officer
17 Sep. 2024 J. Molner AS Consolidated interim report for the first 6 months of 2024 (unaudited)
2 Sep. 2024 J. Molner Announces New President North America at The J. Molner Company LLC
28 Jun. 2024 Additional increase of The J. Molner Company OÜ voluntary reserve
21 Jun. 2024 Decisions of the shareholders - adoption of resolutions of the General Meeting without calling a meeting
5 Jun. 2024 J. Molner AS notice regarding the adoption of the decision of the general meeting of shareholders without calling the meeting 2023
30 Apr. 2024 J. Molner AS Gains US FDA Approval for First Estonian-Developed ANDA - Lidocaine Hydrochloride Topical Solution 4%
24 Apr. 2024 J. Molner AS Audited Consolidated Annual Report 2023
1 Apr. 2024 J. Molner AS Consolidated Unaudited Interim balance sheet for the 2 Months of 2024 and increase of The J. Molner Company OÜ voluntary reserve
28 Mar. 2024 J. Molner AS Consolidated Unaudited Interim Report for the 12 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve
4 Mar. 2024 J. Molner has entered into an agreement with the US Centers for Medicaid and Medicare Services (CMS)
10. Jan. 2024 The subsidiary of J. Molner AS The J. Molner Company OÜ was granted an additional loan
15 Nov. 2023 J. Molner AS Enters the US Market with Hydrocortisone Butyrate Lotion, 0.1%
15 Sep. 2023 J. Molner AS Consolidated Unaudited Interim Report for the First 6 Months of 2023 and increase of The J. Molner Company OÜ voluntary reserve
6 Sep. 2023 J. Molner Signs Licensing Agreement for Five Approved Drugs in the US
2 Aug. 2023 Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ
13 Jul. 2023 J. Molner submits drug application to U.S Food and Drug Administration (FDA)
8 Jun. 2023 J. Molner AS Announces Historic Milestone: Receives Health Canada Approval for its First Drug, Norepinephrine Bitartrate Injection
28 Apr. 2023 Restructuring in the employee structure of J.Molner AS subsidiary The J. Molner Company OÜ
20 Apr. 2023 J.Molner AS Resolutions of annual general meeting
10 Apr. 2023 J.Molner concludes loan agreement extending the existing credit facility of The J. Molner Company OÜ
6 Apr. 2023 J. Molner announces licensing agreement for generic injectable drugs with Juno Pharmaceuticals in Canada
28 Mar. 2023 Notice of calling the annual general meeting of the shareholders
28 Mar. 2023 J.Molner submits second drug to Health Canada
17 Mar. 2023 J.Molner AS comments on the observation status applied on J.Molner AS shares on March 10, 2023 by Nasdaq Tallinn
10 Mar. 2023 J.Molner AS Audited Annual Reports 2022
10 Mar. 2023 J.Molner AS Unaudited Interim Reports 2022
9 Jan. 2023 J. Molner AS executes planned reorganization transaction
30 Nov. 2022 The first day of trading with new shares of J.Molner AS is 01.12.2022
14 Nov. 2022 FDA formally registers transfer to J. Molner AS of 3 drugs
7 Nov. 2022 Results of the initial public offering of J. Molner AS shares
27 Oct. 2022 J. Molner AS comment about the tenure of Jason Grenfell-Gardner at Teligent, Inc
24 Oct. 2022 Notice of initial public offering of J. Molner AS shares
19 Oct. 2022 Conditional admission to trading of J.Molner AS shares on Nasdaq Baltic Alternative market First North
